MONTREAL, Jan. 16 /PRNewswire/ - TrialStat Corporation, a clinical data management on demand company, today announced that it has been selected by Montreal-based Center for Risk Research (CRR) Inc. as the EDC and data management vendor for a Phase IV study on a new treatment for pulmonary arterial hypertension. CRR chose TrialStat for its on demand EDC platform, ClinicalAnalytics(TM) (CA), and comprehensive range of professional data management services. CA enabled CRR to flexibly and rapidly deploy its study in compliance with European data privacy and security regulations. Starting in the United Kingdom and Germany, the three-year Phase IV study will also take place in France, Ireland, Austria, Italy, Greece, Sweden, Finland, Netherlands, Portugal, Spain, Denmark, Belgium, Luxembourg, Iceland, Norway and Switzerland.
Founded by Lucien Abenhaim, a former General Director of Health for the Government of France and Member of the Executive Board of the World Health Organization, CRR is a research company that conducts large pharmacoepidemiological studies and provides strategic counsel to some of the world’s largest pharmaceutical and biotechnology companies. CRR is a wholly-owned subsidiary of Paris-based LA-SER sarl, a research firm that conducts pharmacoepidemiological studies in France.
“CA provides our pharmaceutical client with the flexibility and the power we need to address the complex data management requirements of this study,” said Lucien Abenhaim, President, CRR. “The platform’s browser-based configurability combined with TrialStat’s experienced data management team allow us to go from a paper study design to a sophisticated and functional EDC setup in a very short time.”
“We are pleased to be working with CRR on this important study,” said Jonathan Barker, President and CEO, TrialStat. “TrialStat’s powerful, easily configurable EDC platform combined with our comprehensive data management services makes us an ideal fit for Phase IV trials, registries and post-market surveillance.”
ClinicalAnalytics (CA) 4.0, TrialStat’s on demand EDC solution, delivers speed, performance and a host of industry-leading capabilities to give customers the power and flexibility they need to get their clinical trials started quickly and cost effectively. CA 4.0 integrates the web and flexible data capture technologies, including image-based forms and handheld devices. It is the first EDC platform to allow all aspects of the study to be configured, deployed and managed through a browser-based interface, which enables customers to deploy studies in a matter of days.
ABOUT TRIALSTAT
---------------
TrialStat Corporation is a privately held company that delivers clinical data management on demand by combining the company’s software as a service products with its full suite of data management services. CA 4.0 is a robust and scaleable clinical EDC on demand solution used by leading academic and contract research organizations. SRS 4.0(TM) automates systematic reviews using real-time collaboration and management tools to achieve transparent, auditable and reproducible results quickly and cost-effectively. For more information, please visit us at www.trialstat.com.
ABOUT CENTRE FOR RISK RESEARCH and LA-SER sarl
----------------------------------------------
Based in Montreal, CRR Inc. is a research company that conducts large risk management projects for pharmaceuticals and provides strategic counsel to some of the world’s largest pharmaceutical and biotechnology companies in Europe and North America. Paris-based LA-SER conducts pharmacoepidemiological studies in France. Both CRR and LA-SER have been founded by Lucien Abenhaim.
ClinicalAnalytics 4.0 and SRS 4.0 are registered trademarks of TrialStat
Corporation.
TRIALSTAT
CONTACT: Chris Wright, TrialStat Corporation, (613) 741-9990 ext 155,cwright@trialstat.com
